Documente Academic
Documente Profesional
Documente Cultură
Author manuscript
Leukemia. Author manuscript; available in PMC 2017 May 17.
Author Manuscript
Abstract
Children with Down syndrome (DS) are at a 20-fold increased risk for acute lymphoblastic
leukemia (DS-ALL). Although the etiology of this higher risk of developing leukemia remains
largely unclear, the recent identification of CRLF2 and JAK2 mutations and study of the effect of
trisomy of Hmgn1 and Dyrk1a on B-cell development have shed significant new light on the
disease process. Here we focus on the clinical features, biology, and genetics of ALL in children
Author Manuscript
with DS. We review the unique characteristics of DS-ALL on both the clinical and molecular
levels and discuss the differences in treatments and outcomes in ALL in children with DS
compared to those without DS. The identification of new biological insights is expected to pave
the way for novel targeted therapies.
incidence of solid tumors in people with DS is actually lower than in the population without
DS, including all age groups (7, 8). However, there is clear predominance of leukemia
including both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL),
which occur mostly in young patients. Moreover, children with DS are frequently born with
*
Co-corresponding Authors: John D. Crispino, Professor, Division of Hematology/Oncology, Northwestern University, 303 East
Superior Street, 5-113, Chicago, IL 60611, j-crispino@northwestern.edu; Nobuko Hijiya, Professor, Division of Pediatric
Hematology/Oncology, Ann and Robert H. Lurie Children's Hospita,l 225 East Chicago Avenue, Chicago, IL 60611,
NHijiya@luriechildrens.org.
#These authors contributed equally to this review
Conflicts of Interest: Dr. Hijiya is a consultant for Novartis. The other authors report no conflicts of interest.
Lee et al. Page 2
There are also some unique features of ALL in children with DS. These include the
predominance of Caucasians (15), significant rarity of infant ALL (16, 17) and a paucity of
T cell ALL (16-18). Moreover, favorable cytogenetics such as ETV6-RUNX1, double
trisomy (trisomy of 4 and 10) and high hyperdiploidy, as well as unfavorable cytogenetics
such as BCR-ABL1 and MLL rearrangements, are less common in DS-ALL than non-DS
ALL (16-19). In the recent international Ponte di Legno study, which analyzed retrospective
Author Manuscript
data from 16 clinical trials, the majority of the DS subgroup (40.3%) had a normal karyotype
(i.e. other than the constitutional trisomy 21), which is in marked contrast to the low
incidence in non-DS children (6.9%) (17). Standard therapy is generally used for DS-ALL,
but the unique toxicity profiles of patients with DS bring challenges. A recent COG high-
risk ALL study, AALL0232, which included prednisone or dexamethasone, vincristine,
PEG-asparaginase and daunorubicin, and a standard-risk study, AALL0932, with
dexamethasone, vincristine and PEG-asparaginase revealed excessive mortality during the
induction phase in patients with DS (20). After the addition of extensive supportive care
guidelines and leucovorin rescue for intrathecal methotrexate, mortality improved in the
AALL0932 protocol, but not in AALL0232. Based on these studies, the 3-drug combination
is used during induction of DS-ALL patients enrolled on the successor COG high-risk
protocol AALL1131. In contrast, the Ponte di Legno study found no difference in treatment-
Author Manuscript
related mortality between 3-drug induction and 4-drug induction, suggesting that there is no
impact of anthracycline on treatment-related mortality (17). Another important observation
of the Ponte di Legno study is that treatment-related mortality in DS was seen in all phases
of treatment, including maintenance therapy, which rarely leads to death in ALL patients
without DS (17).
Overall, the outcome of DS-ALL patients is worse than that of the general pediatric
population. This difference is attributed to a higher relapse rate (17), which may be a
consequence of dose reduction. For example, it is widely recognized that patients with DS
have a higher incidence of methotrexate toxicity, which is most commonly gastrointestinal
(21). Therefore, high-dose methotrexate is avoided or the dose is titrated in most protocols
(17).
Author Manuscript
Table 1 summarizes the outcome of DS-ALL observed in studies published in the last
decade. At least six different studies reported inferior outcome for the cohort with Down
syndrome. For example, the Ponte di Legno study concluded that patients with DS-ALL had
a higher 8-year cumulative incidence of relapse (26%) compared with the non-DS ALL
reference cohort (15%) from the Dutch Child Oncology Group (DCOG) and the Berlin-
Frankfurt-Muenster (BFM) study groups (17, 18). This study also found that age <6 years,
white blood cell count <10 × 109/L, and the presence of ETV6-RUNX1 were independent
favorable prognostic factors for EFS, while age, ETV6-RUNX1 and high hyperdiploidy
Author Manuscript
were associated with relapse-free survival. Furthermore, the study found a higher 2-year
incidence of treatment-related mortality in the group with DS (7% versus 2% in patients
with DS or non-DS, respectively) that was associated with a lower EFS. Separately, the
Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL92 and the NOPHO
ALL2000 protocols concurred that the 5-year EFS for patients with DS was poorer
compared to those without DS (22). These authors concluded that the physician's lack of
protocol adherence and decreased doses during maintenance phase may have contributed to
the inferior outcome in DS patients. Indeed, the higher relapse rate may be a consequence of
dose reduction.
Although hematopoietic stem cell transplantation (HSCT) remains a viable option for those
with high risk or relapsed ALL, the data on HSCT in patients with DS are limited and the
role in relapsed patients with DS remains unclear (23, 24). New agents with novel
Author Manuscript
Genetics of DS-ALL
Recent studies have provided key insights into other genetic contributions that play a role in
the increased risk for and development of DS-ALL. These alterations include mutations in
JAK2, NRAS and KRAS, mutations or overexpression of CRLF2, and trisomy 21 (Figure 1).
While the specific genes on Hsa21 that participate in B-ALL have been unclear, recent
studies implicate HMGN1 (35), and DYRK1A (36). Several other genetic events have been
found in DS-ALL, including IKZF1 deletion (37, 38), PAX5 deletion (39, 40), ETV6-IGH
Author Manuscript
rearrangement (41), and histone gene deletions (42). Given this extensive list of players
involved in DS-ALL, it is not surprising that prior studies have emphasized the genetic
heterogeneity of this subtype (43). The complexity of DS-ALL is underscored by the
observation that development of an animal model of DS-ALL required the combination of a
Jak2 mutation, CRLF2 overexpression, Pax5 deficiency, Ikzf (Ikaros) loss and the mouse
equivalent of trisomy 21 (35). In the following sections, we review the major genetic
changes involved in DS-ALL and how these affect disease progression.
Alterations in CRLF2
Among the genetic abnormalities implicated in development of DS-ALL, aberrant
expression of cytokine receptor like factor 2 (CRLF2) has been well characterized. CRLF2
is an important lymphoid signaling receptor, which complexes with IL-7Rα to form a
heterodimeric receptor for thymic stromal lymphopoietin (TSLP). Several groups discovered
that CRLF2 is overexpressed or mutated in a subset of B-ALL cases that lack common
translocations such as t(12;21) and t(1;19), particularly DS-ALL (43-46). Overexpression of
CRLF2 is caused by both novel deletions of the pseudoautosomal region (PAR1) of Xp22.3/
Yp11.3 and by immunoglobulin heavy chain translocations. Specifically, the PAR1 deletion
was shown to be adjacent to the CSF2RA and CRFL2 genes. Array-based comparative
genomic hybridization uncovered that the PAR1 deletion resulted in a rearrangement
Author Manuscript
between first non-coding exon of P2RY8 and the entire coding region of CRLF2 (44).
P2RY8 encodes a purinergic receptor that is expressed highly in a variety of tissues; indeed,
this fusion results in higher CRFL2 expression (47). Moreover, CRLF2 overexpression has
also been seen in B-ALL cases due to IGH@-CRLF2 fusion (43, 45). These rearrangements
are fairly rare in non-DS-ALL, but common in DS-ALL with rates of approximately 5% and
50%, respectively. Of note, a point mutation in CRLF2 resulting in F232C was also
identified in approximately 9% of DS-ALL patients and 21% of adult B-ALL patients who
overexpress CRLF2 (43, 46). It is also noteworthy that the CRLF2 abnormality was seen in
nearly 50% of cases of Ph-like ALL, with more than half of these also harboring JAK1/
JAK2 mutations (48). Overall, CRLF2 dysregulation is found in 5-10% of pediatric ALL
and in 60% of DS-ALL, indicating its significant role as an inciting factor in the
development of the DS subtype (49).
Author Manuscript
JAK2 mutations
Mutations in JAK2 are commonly seen in hematopoietic disorders; V617F mutations are
very common in patients with myeloproliferative neoplasms (MPNs), accounting for more
than 90% of polycythemia vera and nearly 50% of essential thrombocythemia and primary
myelofibrosis (50). As JAK-STAT signaling also plays an important role in B
lymphopoiesis, several studies have not surprisingly revealed a role for JAK2 mutations in
the etiology of acute lymphoblastic leukemia, particularly DS-ALL. The first case of a JAK2
activating mutation in a patient with DS with pre-B ALL was described in 2007 (51). The
report revealed the presence of a novel deletion of five amino acids (JAK2∆IREED) within
the JH2 pseudokinase domain from a screen of JAK2 in 90 cases of acute leukemia of
myeloid or B cell origin. The authors demonstrated that expression of this deletion mutant
Author Manuscript
conferred constitutive JAK-STAT signaling to Ba/F3 cells similar to that seen upon V617F
expression, a hallmark of primary myelofibrosis. As the only other genetic event present was
trisomy 21, the patient observations suggest a cooperative relationship between trisomy 21
and JAK2 activation. Next, a 2008 study found that 16 of 88 patients with DS-ALL harbored
R683 mutations in bone marrow specimens, while none of the other 72 samples presented
any other JAK2 exon 16 mutations (52). Of the missense mutations found in these 16
patients, 8 were R683G, 5 were R683S, 1 was R683K, and 2 were large insertions before
R683. It was further revealed in this study that expression of JAK2 mutants in BaF3/EpoR
Why are V617F and R683 mutations restricted to the MPNs and B-ALL, respectively? The
R683 and V617 residues both lie in the JAK2 pseudokinase domain, but on different highly
Author Manuscript
conserved sites (55). The DS-ALL mutations are predicted to affect the interactions with the
C-terminal kinase domain, resulting in constitutive JAK2 activation, similar to the V617F
mutation in the MPNs. Moreover, it is thought that both V617 and R683 mutations disrupt
the interaction of the JAK2 pseudokinase domain with the JH1/JH2 domains, thereby
reducing the intrinsic negative regulatory activity. However, the mechanism behind the
selectivity of these mutations in AML versus ALL is still poorly understood. One report has
described two structural hotspots in the JAK2 pseudokinase domain containing either V617
(hotspot I) or R683 (hotspot II). The authors postulate that mutations in these hotspots, in
addition to activating JAK2, may alter the recruitment to different signaling complexes,
thereby providing a potential mechanism behind the genotype-phenotype specificity of
JAK2 pseudokinase mutations (56).
Author Manuscript
This high incidence of co-occurrence of the two events suggests that there is cooperation
between CRLF2 and JAK2 alterations. Indeed, while expression of P2RY8-CRLF2 or JAK2
mutants alone in Ba/F3-IL7R cells was insufficient to induce cytokine-independent growth,
expression of both led to constitutive JAK-STAT signaling and cytokine independence (44).
Similar experiments were performed in BaF/3 cells that express CRLF2 by co-expression of
wild type JAK2 or the R683S mutant. Although JAK2 R683S expression allowed for
cytokine independent growth, the effect was significantly amplified when R683S was co-
Author Manuscript
expressed with CRLF2 (43). The F232C CRLF2 mutation similarly cooperates with JAK2
mutations in promoting cytokine independent growth (43, 46). However, despite the
prevalence of CRLF2 overexpression and JAK2 activating mutations in DS-ALL, many still
lack these well-characterized lesions, implying that there are other components of the
disease that still require further study, several of which are described below.
Not all cases of CRLF abnormalities are associated with JAK2 mutations. One recent study
reported the identification of mutations in NRAS or KRAS in 15 of 42 DS-ALL cases,
which is similar to the incidence of JAK2 or P2RY8-CRLF2 fusions (58). The RAS
mutations were mutually exclusive with JAK2 mutations. Interestingly, it was found that
JAK2-mutated or PTPN11-mutated sub-clones had switched to a RAS-mutant clone in two
of three relapsed cases. The interplay between these multiple signaling mechanisms
highlights both the complexity and the importance of the CRLF2-JAK2 axis in promoting
leukemic potential.
While trisomy 21 is clearly associated with leukemia, the specific gene(s) on this
chromosome that promotes B-ALL when present in three copies remains unclear. Two
Author Manuscript
recent studies have implicated specific Hsa21 genes, HMGN1 and DYRK1A, in
lymphopoiesis and the disease process (35, 36).
accumulation of B cells in the less mature Hardy A fraction with concomitant reductions in
Author Manuscript
the more mature B and C fractions in the Ts1Rhr mice (35). There was also an overall
reduction in B cell numbers. Next, they investigated the colony forming activity of B cell
progenitors and made the surprising observation that pre-B cells from the trisomic animals
had the ability to re-plate for at least 10 generations, despite the reduction in their overall
numbers. This re-plating phenotype indicates that the presence of three alleles of one (or
more) of the 31 trisomic genes confers progenitor B cell self-renewal. Finally, they
introduced the BCR-ABL oncogene into disomic or Ts1Rhr bone marrow and transplanted
the cells to irradiated recipients. BCR-ABL expression in the Ts1Rhr genotype gave rise to a
disease with shorter latency and increased penetrance than in euploid controls.
Several lines of evidence suggest that Hmgn1 is one of the critical trisomic genes that alters
B-cell development in Ts1Rhr mice. First, shRNAs against Hmgn1 were selectively depleted
during Ts1Rhr pre-B cell colony replating (35). This argues that persistent expression of the
Author Manuscript
Interestingly, it has been reported that trisomy 21 in human fetal liver is associated with
impaired B cell development as evidenced by a reduction in committed B-lineage
Author Manuscript
The dual specificity kinase DYRK1A—One of the major players in the neuronal
pathogenesis of DS is DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase
1A), transcribed from the DSCR of chromosome 21 (63). A member of the CMGC
superfamily, DYRK1A has been well characterized in various tissues, particularly
neurological models, with roles including cell proliferation and differentiation (64), RNA
splicing (65), and apoptosis (66). DYRK1A was not studied in hematopoiesis until an
Author Manuscript
AMKL-promoting role for the kinase was discovered by virtue of its dysregulation of
nuclear factor of activated T cells (NFAT) activity (60). While this inhibition of NFAT
signaling by DYRK1A has canonically been linked to lower incidence of cancers in adults
with DS (67), the data in this former study suggests that increased NFAT dysregulation
promotes AMKL in children with DS, thereby providing evidence for DYRK1A having both
cancer-promoting and cancer-inhibitory activities.
DYRK1A may play a role in promotion of ALL, but, likely through a pathway different
Author Manuscript
from that in AMKL, as Dyrk1a was recently shown to be essential for lymphoid, but not
myeloid, cell development (36). Ablation of Dyrk1a in the proliferative stages of pre-B and
pre-T cells led to a transcriptional up-regulation of cell cycle-promoting genes. However,
while these cells appeared to be in the S-G2-M cycling state, there was a decrease in total
cell number and an inability of pre-B colonies to proliferate ex vivo. There have been
previous studies suggesting a significant role for DYRK1A in cell cycle regulation in other
tissues, such as phosphorylation of Lin52 (S28) and consequential assembly of the cell cycle
regulatory DREAM complex (68) or phosphorylation and stabilization of p27 (69). Within
developing lymphocytes, DYRK1A phosphorylates cyclin D3 on T283, a highly conserved
phosphodegron site among D-type cyclins (36). Furthermore, degradation of phosphorylated
cyclin D3 was associated with repression of E2F target genes. This finding complements a
previous study, which showed that DYRK1A phosphorylation of cyclin D1 on the
Author Manuscript
homologous T286 induced G0 cell cycle exit and differentiation of fibroblasts (70). Thus by
negatively regulating cyclin D3 stability, DYRK1A plays a major role shifting lymphocytes
from proliferation to quiescence. Despite the fact that Dyrk1a deficient cells fail to enter
quiescence, they did not accumulate in the animal (36). Rather, large pre-B cells lacking
Dyrk1a completed fewer cell divisions than control cells, indicating that DYRK1A has
additional roles in cell growth. The requirement for Dyrk1a in lymphopoiesis suggests that it
may be a novel target for therapeutic intervention. Importantly, loss of Dyrk1a had no effect
on the myeloid lineages, further supporting the potential of DYRK1A inhibition as a
targeted therapy for ALL.
several other genetic events that have been observed. Among these, deletions of IKZF1 and
PAX5 are often cited, both of which are prevalent in non-DS-ALL (39, 71). While loss of
IKZF1 alone does not lead to development of B-ALL, in the context of BCR-ABL1, IKZF1
haploinsufficiency reduced the latency in development of B-ALL in transgenic mice (37).
Similarly, deletion of IKZF1 has been observed in approximated 75% of BCR-ABL1
positive- BALL cases. This finding suggests that while loss of IKZF1 is not a primary event
in leukemic development, it may be an essential secondary event. In murine models, it has
been shown that the dominant-negative isoform tends to have a more severe leukemic
phenotype, although haploinsufficiency accelerates the development of leukemia (37). Thus
despite the different effects of these deletions, both cases are strongly implicated in
hematologic neoplasia. In DS-ALL patients, the frequency of IKZF1 deletions (26-35%) is
comparable to high-risk non-DS-ALL patients (29%) based on independent cohorts from the
Author Manuscript
Dutch Childhood Oncology Group (DCOG) and UK trials (39). Interestingly, compared to
B-ALL patients, DS-ALL patients have a significantly lower incidence of combined IKZF1
deletion and JAK2 mutations, which provides further evidence that genetic patterns
causative of DS-ALL differ significantly from non-DS-ALL. PAX5 is another gene involved
in B-cell development that has been implicated in DS-ALL. Analysis of the DCOG cohorts
revealed deletions in PAX5 in 12% of DS-ALL patients, and the event was not mutually
exclusive to IKZF1 deletions (39). Though this frequency is less than what is observed in B-
iAMP21
Another causative genetic event in ALL that is related to DS-ALL is an intrachromosomal
amplification of chromosome 21 (iAMP21), which has been reported in 2% of pediatric
ALL (72). iAMP21 rarely arises from a germline Robertsonian translocation, rob(15;21)
(q10,q10)c, or more commonly is sporadically initiated by breakage-fusion-bridge (BFB)
repair cycles. Both of these events display evidence of chromothripsis as an inciting
mechanism (73) and may result in duplications of the abnormal chromosome, providing an
optimal gene dosage for leukemogenesis. While rob(15;21)c only accounts for 0.5-1% of all
Robertsonian translocations, patients with this chromosomal abnormality have a ∼2700-fold
increased risk in developing iAMP21-ALL (73). Genetic analysis of patients with iAMP21
Author Manuscript
has revealed several interesting patterns. For example, one study showed that while RUNX1
is often found in the amplified region of patients with iAMP21, and RUNX1 translocations
with ETV6 are commonly associated with ALL, RUNX1 mutations are generally not seen in
iAMP21 (74). Similarly JAK mutations were seen in none of the 15 iAMP ALL patients in
that study. Additionally, of 94 samples from iAMP21 patients, the group observed IKZF
deletions (16%), PAX5 deletions (8%), CDKN2A deletions (13%), ETV6 deletions (15%),
RB1 deletions (13%), gain of X chromosome (20%), and P2RY8-CRLF2 fusion (17%).
Moreover, although iAMP21 has always been characterized in patients with non-DS-ALL,
many of the genes amplified are in the DSCR of chromosome 21, such as RUNX1 and
miR-802. Another study that analyzed a minimal iAMP region revealed that that the most
highly amplified regions of chromosome 21 includes RUNX1, DYRK1A and ETS2 (73).
Certain genetic elements that are characteristic of DS-ALL are also seen in similar
Author Manuscript
frequency in iAMP21 ALL, most notably gain of X chromosome (20% in iAMP21 ALL,
24% in DS-ALL) and P2RY8-CRLF2 fusion (17% in iAMP21 ALL, 22% in DS-ALL) (74).
Nevertheless, there are still glaring differences, such as the lack of JAK mutations in
iAMP21, despite the high rate of occurrence in DS-ALL. Thus the differences between
iAMP21 ALL and DS-ALL underscore the complexity of genetic events involved in B-cell
leukemia.
risk for relapse and for severe side effects as a consequence of their hypersensitivity to
conventional chemotherapy. In contrast to DS-AMKL, which has a well-defined genetic
basis of GATA1 mutations on the X chromosome (10), the pathogenesis of DS-ALL is far
more complex. Development of an animal model of DS-ALL required four events beyond
trisomy: CRLF2 overexpression, a Jak2 mutation, and losses of Pax5 and Ikzf (35).
There are many questions to consider as we move towards novel therapies for DS-ALL.
First, what are the specific genes that contribute to the leukemia predisposition? The study
gene, while the study by Thompson et al provided evidence that DYRK1A is at least
required for B-ALL. There are 29 other candidate genes in the Ts1Rhr model and well over
100 others from Hsa21 that need to be considered. With the advent of CRISPR technology, it
is likely that experiments to identify the genes in an unbiased fashion will more quickly
forward. Second, why is there a strong link between JAK2 mutations and CRLF2
alterations? Third, why are there different categories of JAK2 mutations in ALL versus the
MPNs? Finally, what does the future hold with respect to novel and more effective therapies
for DS-ALL? Studies to test JAK inhibitors, CAR-T cells, and immunomodulatory agents
that are ongoing or planned will certainly advance the field. Given the multitude of health
issues that individuals with DS face, it is imperative that we move aggressively forward to
find less toxic and more efficacious treatments.
Author Manuscript
Acknowledgments
This review was supported by grants from the National Institutes of Health (R01 CA101774, JC), the Rally and
Bear Necessities Foundations (JC), the Unites States - Israel Binational Science Foundation (SI and JC), the Samuel
Waxman Cancer Research Foundation (SI and JC), the Israel Science Foundation Legacy Program (SI), the Israel
Cancer Research Foundation (SI), and Children with Cancer UK (SI). This review is also supported in part by an
Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship.
References
1. Seewald L, Taub JW, Maloney KW, McCabe ER. Acute leukemias in children with Down
syndrome. Molecular Genetics & Metabolism. 2012; 107(1-2):25–30. [PubMed: 22867885]
2. Ross JA, Spector LG, Robison LL, Olshan AF. Epidemiology of leukemia in children with Down
syndrome. Pediatr Blood Cancer. 2005; 44(1):8–12. [PubMed: 15390275]
3. Vis JC, Duffels MG, Winter MM, Weijerman ME, Cobben JM, Huisman SA, et al. Down syndrome:
a cardiovascular perspective. Journal of Intellectual Disability Research. 2009; 53(5):419–25.
Author Manuscript
[PubMed: 19228275]
4. Watt T, Robertson K, Jacobs RJ. Refractive error, binocular vision and accommodation of children
with Down syndrome. Clin Exp Optom. 2015; 98(1):3–11. [PubMed: 25395109]
5. Ferreira-Vasques AT, Lamônica DA. Motor, linguistic, personal and social aspects of children with
Down syndrome. Journal of Applied Oral Science. 2015; 23:424–30. [PubMed: 26398516]
6. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's
syndrome. British journal of Haematology. 2000; 110:512–24. [PubMed: 10997960]
7. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with
Down's syndrome. Lancet. 2000; 355(9199):165–9. [PubMed: 10675114]
8. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA
from 1983 to 1997: a population-based study. Lancet. 2002; 359(9311):1019–25. [PubMed:
11937181]
9. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid
leukemia and transient myeloproliferative disease differs significantly from other diseases with
Author Manuscript
13. Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, et al. Preserved High Probability
of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down
Syndrome: A Nationwide Prospective Study in Japan. Pediatric Blood & Cancer. 2016; 63:248–54.
[PubMed: 26481183]
14. Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, et al. GATA1, cytidine deaminase,
and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl
Cancer Inst. 2005; 97(3):226–31. [PubMed: 15687366]
15. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome
childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that
influences treatment outcome: a report from the Children's Oncology Group. Blood. 2010; 116(7):
1045–50. Epub 2010/05/06. [PubMed: 20442364]
16. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia
in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005; 128(6):
797–804. [PubMed: 15755283]
Author Manuscript
17. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink
MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective
analysis from the Ponte di Legno study group. Blood. 2014; 123(1):70–7. Epub 2013/11/14.
[PubMed: 24222333]
18. Arico M, Ziino O, Valsecchi MG, Cazzaniga G, Baronci C, Messina C, et al. Acute lymphoblastic
leukemia and Down syndrome: presenting features and treatment outcome in the experience of the
Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer. 2008; 113(3):515–
21. [PubMed: 18521927]
19. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, et al. Different
drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood
mononuclear cells in children with and without Down syndrome. Blood. 2002; 99(1):245–51.
[PubMed: 11756178]
20. Maloney KW, Wood B, Whitlock JA, Loh M, Raetz EA, Winick N, et al. Event free (EFS) and
overall survival (OS) for children with Down syndrome (DS) and B-lymhoblastic leukemia in
Children's Oncology Group (COG) trials AALL0232 and AALL0331. Pediatric Blood & Cancer.
Author Manuscript
expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and
young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517–28. [PubMed:
25319501]
26. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell
therapy for acute lymphoblastic leukemia. Blood. 2015; 125(26):4017–23. [PubMed: 25999455]
27. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid
malignancies. Nature Reviews Clinical Oncology. 2016; 13(1):25–40.
28. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T
cells for sustained remissions in leukemia. New England Journal of Medicine. 2014; 371(16):
Author Manuscript
mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;
120(17):3510–8. [PubMed: 22955920]
34. Tasian SK, Doral MY, Borowitz MJ, Wood BL, Chen IM, Harvey RC, et al. Aberrant STAT5 and
PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute
lymphoblastic leukemia. Blood. 2012; 120(4):833–42. [PubMed: 22685175]
35. Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, et al. Triplication of a 21q22 region
contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27
trimethylation. Nat Genet. 2014; 46(6):618–23. Epub 2014/04/22. [PubMed: 24747640]
36. Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, et al. DYRK1A
controls the transition from proliferation to quiescence during lymphoid development by
destabilizing Cyclin D3. J Exp Med. 2015; 212(6):953–70. Epub 2015/05/27. [PubMed:
26008897]
37. Olsson L, Johansson B. Ikaros and leukaemia. Br J Haematol. 2015; 169(4):479–91. Epub
2015/03/11. [PubMed: 25753742]
38. Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, et al. IKZF1 deletion is
Author Manuscript
associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in
Japan. Cancer medicine. 2013; 2(3):412–9. Epub 2013/08/10. [PubMed: 23930217]
39. Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, et al.
Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1
deletions and CRLF2 aberrations. Leukemia. 2012; 26(10):2204–11. [PubMed: 22441210]
40. Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al.
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute
lymphoblastic leukemia. Blood. 2009; 113(3):646–8. Epub 2008/10/18. [PubMed: 18927438]
41. Tirado CA, Shabsovich D, Kim Y, Traum P, Pullarkat S, Kallen M, et al. A case of B-cell acute
lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving
ETV6 and biallelic IGH@ rearrangements. Biomarker research. 2015; 3:11. Epub 2015/07/24.
[PubMed: 26203356]
42. Loudin MG, Wang J, Leung HC, Gurusiddappa S, Meyer J, Condos G, et al. Genomic profiling in
Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with
Author Manuscript
45. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated
expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell
Author Manuscript
56. Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical
genetics to develop inhibitors of Janus kinases. Journal of Cellular & Molecular Medicine. 2010;
14(3):504–27. [PubMed: 20132407]
57. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, et al. Gain-of-function
mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J
Exp Med. 2011; 208:901–8. [PubMed: 21536738]
58. Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, et al. Frequent cases of
RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nature
communications. 2014; 5:4654.
59. Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, et al. Highly penetrant
myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008; 111(2):
767–75. [PubMed: 17901249]
60. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, et al. Increased
dosage of the murine chromosome 21 orthog Dyrk1a promotes megakaryoblastic leukemia in
Down syndrome. Journal of Clinical Investigation. 2012; 122(3):948–62. [PubMed: 22354171]
Author Manuscript
61. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of
pro-B and pre-pro-B cell stages in normal mouse bone marrow. Journal of Experimental Medicine.
1991; 173(5):1213–25. [PubMed: 1827140]
62. Roy A, Cowan G, Mead AJ, Filippi S, Bohn G, Chaidos A, et al. Perturbation of fetal liver
hematopoietic stem and progenitor cell development by trisomy 21. Proceedings of the National
Academy of Sciences of the United States of America. 2012; 109(43):17579–84. [PubMed:
23045701]
63. Abbassi R, Johns TG, Kassiou M, Munoz L. DYRK1A in neurodegeneration and cancer:
Molecular basis and clinical implications. Pharmacology & therapeutics. 2015; 151:87–98. Epub
Author Manuscript
promotes quiescence and senescence through DREAM complex assembly. Genes & Development.
2011; 25(8):801–13. [PubMed: 21498570]
69. Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor FJ, Becker W. The Down
syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces
cell cycle exit and neuronal differentiation. Cell Cycle. 2014; 13(13):2084–100. [PubMed:
24806449]
70. Chen JY, Lin JR, Tsai FC, Meyer T. Dosage of Dyrk1a shifts cells within a p21-cyclin D1
signaling map to control the decision to enter the cell cycle. Mol Cell. 2013; 52(1):87–100.
[PubMed: 24119401]
71. Mullighan CG. The genomic landscape of acute lymphoblastic leukemia in children and young
adults. Hematology. 2014; 2014(1):174–80. [PubMed: 25696852]
72. Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BE, Kinsey SE, et al. Prognosis
of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of
chromosome 21 (iAMP21). Blood. 2007; 109(6):2327–30. Epub 2006/11/11. [PubMed:
17095619]
Author Manuscript
73. Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM, Jacobs P, et al. Constitutional and
somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature. 2014;
508(7494):98–102. Epub 2014/03/29. [PubMed: 24670643]
74. Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, et al. Genomic characterization
implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute
lymphoblastic leukemia. Blood. 2011; 117(25):6848–55. [PubMed: 21527530]
75. Patrick K, Wade R, Goulden N, Rowntree C, Hough R, Moorman AV, et al. Outcome of Down
syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. British
Journal of Haematology. 2014; 165(4):552–5. [PubMed: 24428704]
76. Lundin C, Forestier E, Klarskov Andersen M, Autio K, Barbany G, Cavelier L, et al. Clinical and
genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic
countries. Journal of hematology & oncology. 2014; 7:32. Epub 2014/04/15. [PubMed: 24726034]
77. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics
and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's
Author Manuscript
mutations, many cases of DS-ALL occur without this combination of events. Recent
evidence suggests contributions of trisomy of HMGN1 and DYRK1A and deletions of PAX5
and IKZF (F). Of note, the latter two events were needed in combination with CRLF2
overexpression and a JAK2 activating mutation for development of an animal model of DS-
ALL (35). These genetic alterations exhibit an enormous variability in both nature and
frequency, underscoring the complexity behind the pathogenesis of DS-ALL.
Author Manuscript
Table 1
Summary of published studies on the outcome of DS-ALL
Author Manuscript
UKALL study (75) 3040 non-DS 86 5-year EFS 65.6% DS vs. 87.7% non-DS The study reported 0/28 relapses for
DS 2003-2011 (p<0.00005) patients in the MRD low risk group.
5-year OS 70% DS vs. 92.2% non-DS (P<0.00005)
5-year TRM 21.6% DS vs. 3.3% non-DS,
p<0.00005)
NOPHO (76) 4637 non-DS 128 5year-EFS(SE) 0.574 (0.057) DS vs. 0.783 (0.008) B-precursor ALL only
DS 1981-2010 non-DS (P<.001)
5-year OS 0.691 (0.054) DS vs.0.894 (0.006) non-
DS (P<.001)
COG (15) 2731 non-DS 80 5-year EFS 69.9%±8.6% DS vs. 78.1%±1.2% non- B-precursor ALL only
Author Manuscript
AIEOP (18) 6237 non-DS 119 10 year EFS (SE) 55.8% (4.9%) DS vs. 69.7% B-precursor ALL only
DS 1982-2004 (0.7%) non-DS
10 year OS (SE) 60.4% (5.1%) DS vs. 79.7% (0.6%)
non-DS
CCG (77) 8268 non-DS 179 10 year EFS Standard risk 56.29±6% DS vs. Includes 8 DS and 747 non-DS with
DS 1983-1995 73.48±0.7% non-DS (P<.001) T-ALL
High-risk 62.06±6.5% DS vs. 59.29±0.9% non-DS
P=.9
10 year OS Standard risk 70.17±4.9% DS vs.
84.87±0.6% non-DS (P<.001)
High-risk 63.32±7.1% DS vs. 65.49±1% non-DS
P=.7
Abbreviations: DS; Down syndrome, SE; standard error, OS; overall survival, EFS; event-free survival, TRM; treatment-related mortality; AIEOP;
Italian Association of Pediatric Hematology Oncology; NOPHO; Nordic Society of Pediatric Hematology Oncology; DCOG; Dutch Child
Author Manuscript